Media headlines about Eleven Biotherapeutics (NASDAQ:EBIO) have been trending somewhat positive on Saturday, according to Accern Sentiment. The research group scores the sentiment of media coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Eleven Biotherapeutics earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 47.0501024684277 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.

Eleven Biotherapeutics (EBIO) opened at 1.11 on Friday. Eleven Biotherapeutics has a 52-week low of $0.90 and a 52-week high of $4.78. The firm has a 50-day moving average of $1.33 and a 200-day moving average of $1.65. The stock has a market capitalization of $17.09 million, a PE ratio of 10.18 and a beta of 3.39.

Eleven Biotherapeutics (NASDAQ:EBIO) last released its quarterly earnings results on Monday, August 14th. The biopharmaceutical company reported ($0.30) earnings per share for the quarter. Eleven Biotherapeutics had a net margin of 11.28% and a return on equity of 4.26%. On average, equities analysts expect that Eleven Biotherapeutics will post ($1.75) EPS for the current year.

A number of equities analysts have weighed in on EBIO shares. Zacks Investment Research raised shares of Eleven Biotherapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, May 16th. ValuEngine cut shares of Eleven Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, June 13th.

TRADEMARK VIOLATION NOTICE: This story was first posted by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally stolen and republished in violation of U.S. and international copyright & trademark legislation. The original version of this story can be viewed at

About Eleven Biotherapeutics

Eleven Biotherapeutics, Inc is a preclinical-stage biopharmaceutical company. The Company applies its AMP-Rx platform to the discovery and development of protein therapeutics to treat diseases of the eye. The Company’s product candidate, which is still in preclinical development, is EBI-031, which was designed, engineered and generated using its AMP-Rx platform and are developing as an intravitreal injection for diabetic macular edema (DME) and uveitis.

Insider Buying and Selling by Quarter for Eleven Biotherapeutics (NASDAQ:EBIO)

Receive News & Ratings for Eleven Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eleven Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.